Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies
← catalyst calendarSponsored by ModernaTX, Inc. (industry) · MRNA — their whole pipeline →. With AstraZeneca.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
134actual
Sites
24
Countries
Australia, Israel, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-11-27 | actual | When the study began enrolling |
| Primary completion | 2025-08-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-01 | actual | The whole study's end, after follow-up |
| First posted | 2018-11-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
- Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Interventions
- Biological: mRNA-2752
- Biological: Durvalumab
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with Dose Limiting Toxicities (DLTs)
measured Up to Day 28
Number of Participants with Adverse Events (AEs)
measured Up to 27 months
Arm B: Overall Response Rate (ORR): Percentage of Participants with Tumor Response (Partial or Complete) Based on Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) in Cutaneous Melanoma
measured Up to 2 years
Publications
- PMID 34311780 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · MRNA's whole pipeline · Catalyst calendar · Every registered study · What changed